DWHP invests in electrophysiology testing devices provider LKC

• LKC manufactures electrophysiology testing devices used as an aid in the diagnosis and management of retinal and optic nerve diseases
• With headquarters in Toronto and Park City, Utah, DWHP is a private equity firm focused on investing in the healthcare industry

DW Healthcare Partners has made an investment in Gaithersburg, Maryland-based LKC Technologies, a maker of electrophysiology testing devices. No financial terms were disclosed.

LKC manufactures electrophysiology testing devices used as an aid in the diagnosis and management of retinal and optic nerve diseases, such as diabetic retinopathy and glaucoma.

Dina Dubey is transitioning into the role as CEO.

“We are really looking forward to this partnership with LKC,” said Gabe Becher, managing director at DWHP, in a statement. “We believe the company is in the early stages of a tremendous global growth opportunity. LKC’s innovative products help preserve vision by offering technology that makes functional retinal assessments.”

With headquarters in Toronto and Park City, Utah, DWHP is a private equity firm focused on investing in the healthcare industry. The firm has more than $1.6 billion in aggregate capital commitments across all funds since inception.